Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

3.05
-0.1500-4.69%
Post-market: 3.050.00000.00%16:20 EDT
Volume:1.35M
Turnover:4.13M
Market Cap:291.58M
PE:-2.54
High:3.20
Open:3.20
Low:3.00
Close:3.20
52wk High:8.59
52wk Low:2.74
Shares:95.60M
Float Shares:79.40M
Volume Ratio:0.77
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2031
EPS(LYR):-3.9514
ROE:-32.54%
ROA:-8.59%
PB:0.96
PE(LYR):-0.77

Loading ...

Myriad says Precise MRD ovarian cancer test predicts recurrence risk after adjuvant therapy

Reuters
·
Apr 09

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

GlobeNewswire
·
Apr 09

FDA approves Myriad MyChoice CDx as Zejula companion diagnostic for advanced ovarian cancer

Reuters
·
Mar 18

Myriad Genetics Receives FDA Approval of the Mychoice Cdx Test as the Companion Diagnostic for Zejula (Niraparib) for Patients With Ovarian Cancer

THOMSON REUTERS
·
Mar 18

Veracyte Appoints Kevin Haas as Chief Development and Technology Officer

MT Newswires Live
·
Mar 17

Veracyte appoints Kevin Haas as chief development and technology officer

Reuters
·
Mar 17

Myriad Genetics Earnings Call Highlights Growth Amid Headwinds

TIPRANKS
·
Mar 03

Myriad Genetics Launches Precise MRD Test With Select Community Oncologists

Reuters
·
Mar 03

Insider Move at Myriad Genetics Sparks Fresh Investor Buzz

TIPRANKS
·
Feb 28

Myriad Genetics Director S. Louise Phanstiel Acquires Common Shares

Reuters
·
Feb 28

BRIEF-Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing

Reuters
·
Feb 25

Myriad Genetics Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Feb 25

UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating

MT Newswires Live
·
Feb 24

Myriad Genetics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 24

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Myriad Genetics (MYGN)

TIPRANKS
·
Feb 24

Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests

Reuters
·
Feb 24

Myriad Genetics, Inc. : Wells Fargo Cuts Target Price to $6 From $6.5

THOMSON REUTERS
·
Feb 24

Top Premarket Gainers

MT Newswires Live
·
Feb 24

Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN)

TIPRANKS
·
Feb 24

Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating

TIPRANKS
·
Feb 24